Clinical trial protocol synopses
Clinical trial protocol synopses
Browse our clinical trial protocol synopses
Loading…
- Filaria: river blindness
![clinical trials icon](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/06/clinical-trials-people.png)
DNDI-TYL-01
Tylamac phase-II trial for treatment of onchocerciasis
- Democratic Republic of Congo, Africa
- Cutaneous leishmaniasis
![clinical trials icon](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/06/clinical-trials-people.png)
DNDi-MILT-08-CL
Efficacy and safety of thermotherapy plus miltefosine for cutaneous leishmaniasis in South America
- Colombia, Latin America, Peru
- Hepatitis C
![Translation project phase](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/03/translation.png)
DNDi-RDV-04-HCV
Bioequivalence study of test and reference ravidasvir for chronic HCV (in healthy fed participants)
- Asia, Malaysia
- Sleeping sickness
![Translation project phase](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/03/translation.png)
DNDi-OXA-07-HAT
A drug-drug interaction study of acoziborole for T. b. gambiense sleeping sickness (in healthy male participants)
- Asia, Malaysia
- Sleeping sickness
![clinical trials icon](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/06/clinical-trials-people.png)
DNDi-OXA-05-HAT
Pharmacokinetics, efficacy, safety, and tolerability of acoziborole in children with T. b. gambiense sleeping sickness
- Africa, Democratic Republic of Congo
- Sleeping sickness
![clinical trials icon](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/06/clinical-trials-people.png)
DNDi-OXA-04-HAT
Safety and tolerability of acoziborole for seropositive non-parisitologically confirmed T. b. gambiense sleeping sickness
- Africa, Democratic Republic of Congo, Guinea
- Visceral leishmaniasis
![clinical trials icon](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/06/clinical-trials-people.png)
DNDi-MILT/PM-01-VL
Efficacy and safety of paromomycin plus miltefosine or sodium stibogluconate for visceral leishmaniasis in Africa
- Africa, Ethiopia, Kenya, Uganda, Sudan
- Visceral leishmaniasis
![Translation project phase](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/03/translation.png)
DNDi-LXE408-02-VL / CLXE408A12202R
Efficacy, safety and pharmacokinetics of LXE408 for primary visceral leishmaniasis in Ethiopia
- Africa, Ethiopia
- Visceral leishmaniasis
![Translation project phase](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/03/translation.png)
DNDi-LXE408-01-VL / CLXE408A12201R
Efficacy and safety of two LXE408 regimens for primary visceral leishmaniasis in India
- Asia, India
- Hepatitis C
![Translation project phase](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/03/translation.png)
DNDi-RDV-02-HCV
Bioequivalence study of test and reference ravidasvir tablets for chronic HCV (in healthy fed participants)
- Asia, Malaysia
- Chagas disease
![clinical trials icon](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/06/clinical-trials-people.png)
DNDi-FEX-12-CH
Efficacy and safety of fexinidazole for undetermined chronic Chagas disease
- Europe, Spain
- Filaria: river blindness
![Translation project phase](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/03/translation.png)
DNDI-EMO-03
Tolerability, safety, and bioavailability study of immediate release emodepside for river blindness (in healthy participants)
- Europe, United Kingdom
- Filaria: river blindness
![Translation project phase](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/03/translation.png)
DNDI-EMO-02
Safety, tolerability, and pharmacokinetics of emodepside for river blindness (in healthy participants)
- Europe, United Kingdom
- Cutaneous leishmaniasis
![Translation project phase](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/03/translation.png)
DNDi-CpG-001
Safety, tolerability, pharmacokinetics, and pharmacodynamics of CpG ODN D35 for cutaneous leishmaniasis (in healthy participants)
- Europe, United Kingdom
- Cryptococcal meningitis
![Translation project phase](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/03/translation.png)
DNDi-5FC-02-CM
Bioavailability study of immediate release flucytosine for cryptococcal meningitis (in healthy fed participants)
- Africa, South Africa
- Cryptococcal meningitis
![Translation project phase](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/03/translation.png)
DNDi-5FC-01-CM
Bioavailability study of immediate release flucytosine for cryptococcal meningitis (in healthy fasting participants)
- Africa, South Africa
- Cutaneous leishmaniasis, Visceral leishmaniasis
![Translation project phase](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/03/translation.png)
DNDi-6148-01
Safety, tolerability, and pharmacokinetics of single dose DNDI-6148 for visceral leishmaniasis (in healthy participants)
- Europe, France
- Cutaneous leishmaniasis, Visceral leishmaniasis
![Translation project phase](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/03/translation.png)
DNDi‐0690‐02
Safety, tolerability, and pharmacokinetics of multiple dose DNDI-0690 for visceral leishmaniasis (in healthy participants)
- Europe, United Kingdom
- Visceral leishmaniasis
![Translation project phase](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/03/translation.png)
DNDi-0690-01
Safety, tolerability, and pharmacokinetics of single dose DNDI-0690 for visceral and cutaneous leishmaniasis (in healthy participants)
- Europe, United Kingdom
- Pandemic Preparedness
![clinical trials icon](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/06/clinical-trials-people.png)
ANTICOV
Platform trial of efficacy and safety of several therapies for mild / moderate COVID-19
- Africa, Ghana, Guinea, Kenya, Sudan, Uganda, Mali, Brazil, Burkina Faso, Cameroon, Côte d’Ivoire, Democratic Republic of Congo, Ethiopia, Latin America, Tanzania, Mozambique
- Visceral leishmaniasis
![clinical trials icon](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/06/clinical-trials-people.png)
DNDi-MILT COMB-02-PKDL
Efficacy and safety of miltefosine plus either liposomal amphotericin B or paromomycin for PKDL in Sudan
- Africa, Sudan
- Visceral leishmaniasis
![clinical trials icon](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/06/clinical-trials-people.png)
DNDi-MILT COMB-01-PKDL
Efficacy and safety of liposomal amphotericin B alone and in combination with miltefosine for PKDL in Asia
- Asia, Bangladesh, India
- Mycetoma
![clinical trials icon](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/06/clinical-trials-people.png)
DNDi-FOSR-04-MYC
Comparative efficacy of two fosravuconazole doses with itraconazole for eumycetoma, in combination with surgery
- Africa, Sudan
- Chagas disease
![clinical trials icon](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/06/clinical-trials-people.png)
DNDi-CH-E1224-003
Efficacy and safety of shorter benznidazole regimens and E1224 for chronic Chagas disease
- Bolivia, Latin America
- Hepatitis C
![clinical trials icon](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/06/clinical-trials-people.png)
DNDi-SOF/RDV-01-HCV
Efficacy, safety, tolerance, and pharmacokinetics of sofosbuvir plus ravidasvir for chronic HCV
- Asia, Thailand, Malaysia
- Sleeping sickness
![Translation project phase](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/03/translation.png)
DNDi-OXA-03-HAT
Absorption, metabolism, and excretion of acoziborole for sleeping sickness (in healthy participants)
- Europe, United Kingdom
- Sleeping sickness
![clinical trials icon](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/06/clinical-trials-people.png)
DNDi-OXA-02-HAT
Efficacy and safety of acoziborole for T.b. gambiense sleeping sickness
- Africa, Democratic Republic of Congo, Guinea
- Sleeping sickness
![Discovery project phase](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/03/discovery.png)
DNDi-HAT-FEX-006
Efficacy and safety of fexinidazole for T. b. gambiense sleeping sickness in children
- Africa, Democratic Republic of Congo
- Sleeping sickness
![clinical trials icon](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/06/clinical-trials-people.png)
DNDi-HAT-FEX-005
Efficacy and safety of fexinidazole for stage 1 & early stage 2 T. b. gambiense sleeping sickness
- Africa, Democratic Republic of Congo
- Sleeping sickness
![clinical trials icon](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/06/clinical-trials-people.png)
DNDi-FEX-09-HAT
Efficacy, safety and adherence with fexinidazole for any stage of T.b. gambiense sleeping sickness
- Democratic Republic of Congo, Guinea, Africa
- Sleeping sickness
![clinical trials icon](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/06/clinical-trials-people.png)
DNDi-FEX-07-HAT
Efficacy and safety of fexinidazole for T.b. rhodesiense sleeping sickness
- Africa, Uganda, Malawi
- Sleeping sickness
![clinical trials icon](https://mlo1gfdw4hud.i.optimole.com/w:120/h:120/q:eco/f:avif/https://dndi.org/wp-content/uploads/2020/06/clinical-trials-people.png)
DNDi-FEX-004
Efficacy and safety of fexinidazole for late-stage T.b. gambiense sleeping sickness
- Africa
To request access to data from any of DNDi’s clinical trials, please visit the website of our data-sharing partner, Vivli, to make a data request.
Project portfolio
We are working on more than 40 research and treatment access projects, including 20 focused on identifying or developing new chemical entities.
Scientific articles
Loading…
Scientific articles
31 May 2024
Journal of Visualized Experiments
Scientific articles
13 May 2024
Scientific articles
10 May 2024
Transactions of The Royal Society of Tropical Medicine and Hygiene
Scientific articles
8 May 2024
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.